[{"id":"fa138073-4631-4982-9ec7-aa34908ab4fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05473221","created_at":"2022-07-25T20:54:41.104Z","updated_at":"2024-07-02T16:36:06.848Z","phase":"Phase 1","brief_title":"Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML","source_id_and_acronym":"NCT05473221","lead_sponsor":"Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 CAR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 08/02/2024","primary_completion_date":" 08/02/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2022-07-25"},{"id":"60f966ca-31c0-4b48-b372-4939f74290d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05467254","created_at":"2022-07-20T12:56:29.839Z","updated_at":"2024-07-02T16:36:07.070Z","phase":"Phase 1","brief_title":"Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML","source_id_and_acronym":"NCT05467254","lead_sponsor":"Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 CAR-T • CLL1+CD33 CAR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 08/02/2024","primary_completion_date":" 08/02/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2022-07-20"}]